RecruitingPhase 1NCT04794972

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Studying Glial tumor

Last synced from ClinicalTrials.gov May 10, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Principal Investigator: Wenbin Li, DC
Beijing Tiantan Hospital
Intervention: GNC-039(drug)
Enrollment: 60 target
Eligibility: 18 years · All sexes
Timeline: 2021 – 2026

Study locations (6)

Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Affiliated Cancer Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality, China
ZhuJiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
The First Affiliated Hospital of Xi'an Jiao Tong University, Xian, Shanxi, China
West China Hospital，Sichuan University, Chengdu, Sichuan, China

Collaborators

SystImmune Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04794972 on ClinicalTrials.gov

Other trials for Glial tumor

Additional recruiting or active studies for the same condition.

See all trials for Glial tumor →

← Back to all trials